Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc.

Conning Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 279,414 shares of the biopharmaceutical company’s stock after selling 12,061 shares during the period. Gilead Sciences accounts for about 1.1% of Conning Inc.’s holdings, making the stock its 19th largest holding. Conning Inc.’s holdings in Gilead Sciences were worth $34,295,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of GILD. Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences in the fourth quarter valued at $28,000. Financial Consulate Inc. raised its stake in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. boosted its position in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 86 shares in the last quarter. MTM Investment Management LLC grew its stake in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares during the last quarter. Finally, BOCHK Asset Management Ltd acquired a new stake in Gilead Sciences in the 4th quarter valued at about $31,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the transaction, the chief financial officer owned 176,191 shares of the company’s stock, valued at $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,000 shares of company stock worth $9,238,250 over the last quarter. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research reports. Cantor Fitzgerald cut their target price on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 10th. Barclays assumed coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target on the stock. Mizuho lifted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Weiss Ratings raised Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday. Finally, TD Cowen raised their price target on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $157.04.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $132.06 on Friday. The company has a market cap of $163.96 billion, a PE ratio of 17.99 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $97.86 and a 12 month high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The company has a 50-day simple moving average of $138.14 and a 200-day simple moving average of $133.25.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm posted $1.81 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.